Gainers IM Cannabis (NASDAQ:IMCC) stock increased by 246.0% to $6.02 during Friday's regular se

Xenon Pharmaceuticals Inc. (XENE:NASDAQ) shares were down 30%, on Friday morning after the company v

Xenon files an FDA application for azetukalner in epilepsy as its depression studies face a temporar

U.S. stocks fell Friday as weak industrial data weighed; Dow slid 0.45%, materials lagged, energy ro

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) submitted a New Drug Application to the U.S. Food and Drug

Xenon Pharmaceuticals submits an FDA application for azetukalner for seizures while voluntarily paus

RBC Capital analyst Brian Abrahams maintains Xenon Pharmaceuticals (NASDAQ:XENE) with a Outperfor

U.S. stocks mixed Friday: Nasdaq and S&P 500 edged higher, Dow slipped. Oil rose; industrial pro

Wedbush analyst Laura Chico maintains Xenon Pharmaceuticals (NASDAQ:XENE) with a Outperform and l

Stock futures are mixed after last session's rebound, with several Fed officials scheduled to make r

Analysts downgraded Magna, Franklin BSP, and more revising price targets for several.

Analysts downgraded XENE, NFLX and MGA, while raising price targets for OCS, INSW, ABEO and STNG.

Wells Fargo analyst Benjamin Burnett maintains Xenon Pharmaceuticals (NASDAQ:XENE) with a Overwei

Gainers IM Cannabis (NASDAQ:IMCC) stock rose 108.5% to $3.63 during Friday's pre-market session

U.S. stock futures were higher this morning, with the Nasdaq 100 futures gaining around 150 points o

U.S. futures rise, but Xenon plunges 27.6% after pausing psychiatry trial enrollment over neuropsych

Deutsche Bank analyst David Hoang downgrades Xenon Pharmaceuticals (NASDAQ:XENE) from Buy to Hold

Xenon Pharmaceuticals says it paused trials for azetukalner in major depressive disorder and bipolar

TCRT: 69% | Alaunos Therapeutics On Thursday Filed Patent Application "Identification Of Neoanti

Needham analyst Serge Belanger maintains Xenon Pharmaceuticals (NASDAQ:XENE) with a Buy and lower

Baird analyst Brian Skorney maintains Xenon Pharmaceuticals (NASDAQ:XENE) with a Outperform and l

Alaunos rose 21.8% after adopting amended bylaws; Cheetah Net led gainers, while Xenon dropped 27.6%

Xenon Pharmaceuticals shares fell 25% after hours after pausing new patient enrollment in ongoing ps

Xenon Pharmaceuticals Inc. (XENE) Discusses Azetukalner NDA Submission for Focal Seizures and Psychi

Major U.S. indices closed higher on Thursday, with the Dow Jones Industrial Average rising 0.61% to

Gainers Alaunos Therapeutics (NASDAQ:TCRT) shares moved upwards by 30.0% to $2.08 during Thursday&#

Xenon Pharmaceuticals on Thursday said it has temporarily paused enrolling new patients in ​clinical

In addition, the Company announced today that it has implemented a voluntary pause on enrollment for

X-NOVA2 enrollment has reached approximately 80% of its initial target of 450 patients, which is suf

New Drug Application for azetukalner in focal seizures submitted to U.S. Food and Drug Administratio

VANCOUVER, BC and BOSTON, MA, Sept. 17, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:

VANCOUVER, BC and BOSTON, MA, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:

VANCOUVER, BC and BOSTON, MA, Aug. 28, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:

Six presentations planned, including encore oral presentation of topline X-TOLE2 efficacy and safety

VANCOUVER, BC and BOSTON, MA, Aug. 26, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:

BlackRock Inc. bought a new position in shares of Xenon Pharmaceuticals Inc. (NASDAQ: XENE) during t

Xenon Pharmaceuticals (XENE) is upgraded to "Strong Buy" following positive phase 3 X-TOLE2 results

RBC Capital analyst Brian Abrahams maintains Xenon Pharmaceuticals (NASDAQ:XENE) with a Outperfor

10x Genomics reported second-quarter revenue of $151 million, including $1.6 million in license and

Xenon posts a narrower-than-expected Q2 loss as azetukalner advances toward a planned FDA filing, wh

Xenon Pharmaceuticals Inc. (XENE) Q2 2026 Earnings Call Transcript

Xenon Pharmaceuticals (NASDAQ:XENE) reported quarterly losses of $(1.11) per share which beat the an

NDA submission for azetukalner on track for Q3 2026  following pre-NDA meeting with FDA Phase 3 X-TO

VANCOUVER, BC and BOSTON, MA, July 31, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:

VANCOUVER, BC and BOSTON, MA, July 30, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:

Biohaven (BHVN) shares fall as BofA downgrades the stock to Underperform, citing a risky profile ahe

JP Morgan analyst Tessa Romero maintains Xenon Pharmaceuticals (NASDAQ:XENE) with a Overweight an

JP Morgan analyst Tessa Romero maintains Xenon Pharmaceuticals (NASDAQ:XENE) with a Overweight an

RBC Capital analyst Brian Abrahams maintains Xenon Pharmaceuticals (NASDAQ:XENE) with a Outperfor

Needham analyst Serge Belanger maintains Xenon Pharmaceuticals (NASDAQ:XENE) with a Buy and lower